Extreme subcutaneous insulin resistance: A misunderstood syndrome

Diabetes and Metabolism

Volumn 29, Issue 5, 2003, Pages 539-546

  Soudan, B ^a   Girardot, C ^a   Fermon, C ^a   Verlet, E ^a   Pattou, F ^a   Vantyghem, M C ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Dept of Endocrinol and Metabolism ^*  (France)

Author keywords

Insulin degrading enzyme; Intraperitoneal pump; Subcutaneous insulin resistance

Indexed keywords

ANTIFUNGAL AGENT; HEMOGLOBIN A1C; INSULIN; INSULIN LISPRO;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; CASE REPORT; CATHETER INFECTION; CLINICAL FEATURE; DIABETIC RETINOPATHY; DISEASE COURSE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; ENCAPSULATION; EXTREME SUBCUTANEOUS INSULIN RESISTANCE; FEMALE; HUMAN; INFECTION; INSULIN DEGRADATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KETOACIDOSIS; LOW LEVEL LASER THERAPY; NEPHROTOXICITY; NEUROPATHY; SINUSITIS; THROMBOSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VASCULAR DISEASE;

EID: 0345305344     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70069-1     Document Type: Article

References (31)

1. Schneider AJ, Bennett RH. Impaired absorption of insulin as a cause insulin resistance. [Abstract]. Diabetes, 1975, 24, 443.
2. Paulsen EP, Courtney JW, Duckworth WC. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes, 1979, 28, 640-5.
3. Tetaert D, Soudan B, Lo-Guidice JM, et al. Combination of high-performance anion-exchange chromatography and electrospray mass spectrometry for analysis of the in vitro O-glycosylated mucin motif peptide. J Chromatogr, 1994, 658, 31-8.
4. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72, 248-54.
5. Shearer JD, Coulter CF, Engeland WC, Roth RA, Caldwell MD. Insulin is degraded extracellularly in wounds by insulin-degrading enzyme (EC 3.4.24.56). Am J Physiol, 1997, 273, E657-E664.
6. Sapin R, Ongagna JC, Gasser F, Grucker D. Insulin measurements in haemolysed serum: influence of insulinase inhibitors. Clin Acta, 1998, 274, 111-7.
7. Dandona P, Foster M, Healey F, Grecnbury E, Beckett AG. Low-dose insulin infusions in diabetic patients with high insulin infusions requirements. Lancet, 1978, 5, 283-5.
8. Henry DA, Lowe JM, Citrin D, Manderson WG. Defective absorption injectcd insulin. Lancet, 1978, 2, 741.
9. Müller WA, Taillens C, Lereret S, et al. Resistance against subcutaneous insulin successfully managed with aprotinin. Lancet 1980, 7, 1245-6.
10. McElduff A, Eastman CJ, Haynes SP, Bowen KM. Apparent insulin resistance due to abnormal enzymatic insulin degradation: a new mechanism for insulin resistance. Aust N Z J Med, 1980, 10, 56-61.
11. Freidenberg GR, White N, Cataland S, O'Dorisio TM, Sotos JF, Santiago JV. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness a aprotinin. N Engl J Med, 1981, 305, 363-8.
12. Misbin RI, Almira EC, Cleman MW. Insulin degradation in serum of a patient with apparent insulin. J Clin Endocrinol Metab, 1981, 52, 177-80.
13. Maberly GF, Wait GA, Kilpatrick JA, et al. Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient. Diabetologia, 1982, 23, 333-6.
14. Schade DS, Eaton P, Warhol RM, Gregory JA, Doberneck RC. Subcutaneous peritoneal access device for type I diabetic patients nonresponsive to subcutaneous insulin. Diabetes, 1982, 31, 470-3.
15. Campbell IW, Kritz H, Najemnik C, Hagmueller G, Irsigler K. Treatment of type I diabetic with subcutaneous insulin resistance by a totally implantable insuline infusion device ("infusaid"). Diabetes Res, 1984, 1, 83-8.
16. Blazar BR. Whitley CB, Kitabchi AE, et al. In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistrance. Diabetes, 1984, 33, 1133-7.
17. Dandona P, Fonseca V. Fernando O, et al. Control of diabetes through a subcutaneous peritoneal access device (SPAD) in patients with resistance to subcutaneously injected insulin. Diabetes Res, 1987, 5, 47-9.
18. Brossard J, Havrankova J., Rioux D, Bertrand S, D'Amour P. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance. Diabet Med, 1993, 10, 174-6.
19. Riveline JP, Capeau J, Robert JJ, et al. Extreme subcutaneous insulin resistance sucessfully treated by an implantable pump. Diabetes Care, 2001, 24, 2155-6.
20. Schade DS, Duckworth WC. In search of the subcutaneous-insulin-resistance syndrome. N Engl J Med, 1986, 315, 147-52.
21. Schade DS, Drumm DA, Eaton RP, Sterling WA. Factitious brittle diabetes mellitus. Am J Med, 1985, 78, 777-84.
22. Kitabchi AE, Stentz FB, Cole C, Duckworth WC. Accelerated insulin degradation: an alternate mechanism for insulin resistance. Diabetes Care, 1979, 2, 414-7.
23. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev, 1998, 19, 608-24.
24. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the level of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA, 2003, 100, 4162-7.
25. Bennett RG, Hamel FG, Duckworth WC. Insulin inhibits the ubiquitin-dependent degrading activity o the 26S proteasome. Endocrinology, 2000, 141, 2508-17.
26. Hamel FG, Bennett RG, Upward JL Duckworth WC. Insulin inhibits peroxisomal fatty acid oxidation in isolated hepatocytes. Endocrinology, 2001, 142, 2702-6.
27. Fawcett J, Hamel FG, Duckworth WC. Characterization of the inhibition of protein degradation by insulin in L6 cells. Arch Biochem Biophys, 2001, 15, 357-63.
28. Duckworth WC, Hamel FG, Bennett R, Ryan MP, Roth RA. Human red blood cell insulin-degrading enzyme and rat skeletal muscle insulin protease share antigenic sites and generate identical products from insulin. J Biol Chem, 1990, 15, 2984-7.
29. Williams G, Pickup JC, Bowcock S, Cooke E, Keen H. Subcutaneous aprotinin causes local hyperaemia: a possible mechanism by which aprotinin improves control in some diabetic patients. Diabetologia, 1983, 24, 91-4.
30. Antony G, Berdoukas VA, Charlton B, Cooper SG, Gurtünca N, Kelly WH. Plasmapheresis in intractable insulin-resistant diabetes. Lancet, 1983, 2, 1148-9.
31. Pickup JC, Home PD. Bilous RW, Keen H, Alberti KG. Management of severely brittle diabetes by continuous subcutaneous and intramuscular insulin infusions: evidence for a defect in subcutaneous insulin absorption. Br Med J (Clin Res Ed), 1981, 282, 347-50.